Prognostic differences in grading and metastatic lymph node pattern in patients with small bowel neuroendocrine tumors

Langenbecks Arch Surg. 2023 Jun 19;408(1):237. doi: 10.1007/s00423-023-02956-8.

Abstract

Purpose: Neuroendocrine tumors of the small intestine (si-NET) describe a heterogenous group of neoplasms. Based on the Ki67 proliferation index si-NET are divided into G1 (Ki67 < 2%), G2 (Ki67 3-20%) and rarely G3 (Ki67 > 20%) tumors. However, few studies evaluate the impact of tumor grading on prognosis in si-NET. Moreover, si-NET can form distinct lymphatic spread patterns to the mesenteric root, aortocaval lymph nodes, and distant organs. This study aims to identify prognostic factors within the lymphatic spread patterns and grading.

Methods: Demographic, pathological, and surgical data of 208 (90 male, 118 female) individuals with si-NETs treated at Charité University Medicine Berlin between 2010 and 2020 were analyzed retrospectively.

Results: A total of 113 (54.5%) specimens were defined as G1 and 93 (44.7%) as G2 tumors. Interestingly, splitting the G2 group in two subgroups: G2 low (Ki67 3-9%) and G2 high (Ki67 10-20%), displayed significant differences in overall survival (OS) (p = 0.008) and progression free survival (PFS) (p = 0.004) between these subgroups. Remission after surgery was less often achieved in patients with higher Ki67 index (> 10%). Lymph node metastases (N +) were present in 174 (83.6%) patients. Patients with isolated locoregional disease showed better PFS and OS in comparison to patients with additional aortocaval and distant lymph node metastases.

Conclusion: Lymphatic spread pattern influences patient outcome. In G2 tumors, low and high grading shows heterogenous outcome in OS and PFS. Differentiation within this group might impact follow-up, adjuvant treatment, and surgical strategy.

Keywords: GEP-NET; Grading; Lymph node metastases; Si-NET.

MeSH terms

  • Female
  • Humans
  • Ki-67 Antigen
  • Lymph Nodes / pathology
  • Lymphatic Metastasis
  • Male
  • Neoplasm Grading
  • Neuroendocrine Tumors* / pathology
  • Pancreatic Neoplasms* / pathology
  • Prognosis
  • Retrospective Studies

Substances

  • Ki-67 Antigen

Supplementary concepts

  • Gastro-enteropancreatic neuroendocrine tumor